Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)

30 Mar 2025

Abstract excerpt

BACKGROUND: Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic synthesis of lipoprotein(a), are unknown. METHODS: We randomly assigned participants in a 1:2:2:2:2 ratio to receive lepodisiran at a dose of 16 mg, 96 mg, or 400 mg at baseline and again at day 180,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antioxidant Activity and Oxidative Stress
Share to Diabetes, Cardiovascular Risks, and Lipoproteins
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40162643
DOI: 10.1056/nejmoa2415818

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)PMID 40162643Read ↗

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseSemantic proximity Read ↗

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?Semantic proximity Read ↗

Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factorSemantic proximity Read ↗

Treatment of Lp(a): Is It the Future or Are We Ready Today?Semantic proximity Read ↗

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?Semantic proximity Read ↗

Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) MoleculeSemantic proximity Read ↗

Lipoprotein(a)Semantic proximity Read ↗

Lipoprotein(a): more interesting than ever after 50 years.Semantic proximity Read ↗

Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular DiseaseSemantic proximity Read ↗

Updates in Small Interfering RNA for the Treatment of DyslipidemiasSemantic proximity Read ↗

LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging TherapeuticsSemantic proximity Read ↗

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.